Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedJun 29, 2016VERMOX Tablets 100 mgCGMP DeviationsProfarma Distributors LLC · D-1041-2016Class IITerminatedJun 29, 2016tabcin NOCHECGMP DeviationsProfarma Distributors LLC · D-1040-2016Class IITerminatedJun 29, 2016tabcin ACTIVE M.R. CapsulesCGMP DeviationsProfarma Distributors LLC · D-1039-2016Class IIITerminatedJun 22, 2016Pramipexole Dihydrochloride Extended Release TabletsFailed Impurities/Degradation Specifications: Par Pharmaceutical is recalling Pramipexole Dihydrochloride Extended Release tablets because it contains a known product...Par Pharmaceutical · D-1038-2016Class IITerminatedJun 22, 2016Sensorcaine- MPFPresence of Particulate Matter: Glass particulate found in sterile injectable productFresenius Kabi USA, LLC · D-1037-2016Class IIITerminatedJun 22, 2016Lisinopril Tablets USPLabeling: Incorrect or Missing Package InsertSandoz Inc · D-1036-2016Class IIITerminatedJun 22, 2016Chlordiazepoxide HCl/Clidinium Bromide capsulesFailed Impurities/Degradation SpecificationsValeant Pharmaceuticals North America LLC · D-1035-2016Class IIITerminatedJun 22, 2016Librax (5 mg chlordiazepoxide HCl and 2.5 mg clidinium bromide) capsulesFailed Impurities/Degradation SpecificationsValeant Pharmaceuticals North America LLC · D-1034-2016Class IITerminatedJun 22, 2016Vancomycin Hydrochloride for InjectionPresence of Particulate Matter: CardboardHospira Inc. · D-1033-2016Class IIITerminatedJun 22, 2016Lodrane DLabeling: Not Elsewhere Classified: correctly labeled bottles were packaged in cartons that were mislabeled with an incorrect active ingredient, phenylephrine rather...Valeant Pharmaceuticals North America LLC · D-1032-2016Class IIITerminatedJun 22, 2016DoxycyclineLabeling: Incorrect Or Missing Lot and/or Exp Date: Some expiries and lot numbers are missing.Galderma Laboratories, L.P. · D-1031-2016Class IITerminatedJun 22, 2016Nitrofurantoin Oral SuspensionFailed Dissolution SpecificationsNostrum Laboratories, Inc. · D-1030-2016Class IIITerminatedJun 22, 2016HectorolLabeling: Wrong barcode. An incorrect bar code was noted on the vial label of Hectorol 2 mcg/1mL vial.Genzyme Corporation / Genzyme Biosurgery · D-1029-2016Class IITerminatedJun 15, 2016ITRACONAZOLE 0.2%/MUPIROCIN 0.2%/TRIAMCINOLONE 0.03% NASAL SPRAYLack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1028-2016Class IITerminatedJun 15, 2016ITRACONAZOLE 0.2%/MUPIROCIN 0.2% NASAL SPRAYLack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1027-2016Class IITerminatedJun 15, 2016CLOTRIMAZOLE 1%/ BETAMETHASONE DIPROPIONATE 0.05% OTIC SOLUTIONLack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1026-2016Class IITerminatedJun 15, 2016QUAD-MIX #3Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1025-2016Class IITerminatedJun 15, 2016VITAMIN B COMPLEX # 3Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1024-2016Class IITerminatedJun 15, 2016VITAMIN B COMPLEX # 1Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1023-2016Class IITerminatedJun 15, 2016VANCOMYCIN 50MG/ML OPHTH SOLUTIONLack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1022-2016Class IITerminatedJun 15, 2016TRI-MIX # 6Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1021-2016Class IITerminatedJun 15, 2016TRI-MIX # 5Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1020-2016Class IITerminatedJun 15, 2016TRI-MIX # 4Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1019-2016Class IITerminatedJun 15, 2016TRI-MIX # 3Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1018-2016Class IITerminatedJun 15, 2016TRI-MIX # 2Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1017-2016Class IITerminatedJun 15, 2016TRI-MIX # 1Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1016-2016Class IITerminatedJun 15, 2016TESTOSTERONE CYPIONATE 200MG/MLLack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1015-2016Class IITerminatedJun 15, 2016TESTOSTERONE CYPIONATE 175MG/MLLack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1014-2016Class IITerminatedJun 15, 2016TESTOSTERONE CYPIONATE 150MG/MLLack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1013-2016Class IITerminatedJun 15, 2016TESTOSTERONE CYPIONATE 10MG/MLLack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1012-2016Class IITerminatedJun 15, 2016TESTOSTERONE CYPIONATE 100MG/MLLack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1011-2016Class IITerminatedJun 15, 2016SUPER TRI-MIX #4Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1010-2016Class IITerminatedJun 15, 2016SUPER TRI-MIX #1Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1009-2016Class IITerminatedJun 15, 2016QUAD-MIX #4Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1008-2016Class IITerminatedJun 15, 2016QUAD-MIX #2Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1007-2016Class IITerminatedJun 15, 2016QUAD-MIX #1Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1006-2016Class IITerminatedJun 15, 2016PHOSPHATIDYLCHOLINE/DEOXYCHOLIC ACID- 5%/4.75%Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1005-2016Class IITerminatedJun 15, 2016PHENYLEPHERINE 0.5%Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1004-2016Class IITerminatedJun 15, 2016MYERS' COCKTAILLack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1003-2016Class IITerminatedJun 15, 2016METHYLCOBALAMIN/FOLIC ACIDLack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting product quality and sterility.Well Care Compounding Pharmacy · D-1002-2016